ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VAL Valirx Plc

3.55
-0.30 (-7.79%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Valirx Plc LSE:VAL London Ordinary Share GB00BLH13C52 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -7.79% 3.55 3.50 3.60 3.85 3.55 3.85 888,756 16:01:48
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -2.37M -0.0262 -1.35 3.2M

ValiRx PLC New Evaluation Agreement (9162L)

16/09/2021 6:59am

UK Regulatory


Valirx (LSE:VAL)
Historical Stock Chart


From Mar 2021 to Mar 2024

Click Here for more Valirx Charts.

TIDMVAL

RNS Number : 9162L

ValiRx PLC

16 September 2021

16 September 2021

ValiRx PLC ("ValiRx" or the "Company")

Commences new Evaluation Agreement

ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered an Evaluation Agreement with a leading London university to investigate a novel technology designed to treat breast cancer.

Under the agreement, the Company will carry out a defined series of preclinical tests on the drug candidate molecule over the next nine months to validate the technology and determine suitability for commercialisation. This preclinical evaluation, the cost of which will be borne by ValiRx up to GBP75,000, will investigate the action of the molecule against Triple Negative Breast Cancer and other indications.

At the conclusion of the evaluation period the Company has an option to license the technology on pre-agreed terms.

Dr Suzy Dilly, CEO of ValiRx commented "I'm delighted to have secured our next evaluation programme, which, if successful, will achieve the dual objective of building a pipeline in both women's health and oncology. We are also delighted that the Principal Investigator of this exciting technology is keen to remain actively involved in the next stages of development."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                           Tel: +44 (0) 2476 796496 
  Dr Suzanne Dilly, CEO                www.valirx.com 
                                       Suzanne.Dilly@valirx.com 
 Cairn Financial Advisers LLP         Tel: +44 (0) 20 7213 088 
  (Nominated Adviser) 
  Liam Murray/Jo Turner/Ludovico 
  Lazzaretti 
                                     -------------------------- 
 Cenkos Securities Limited (Broker)   Tel: +44 (0) 20 7397 8900 
  Russell Kerr/Michael Johnson 
  (Sales) 
  Callum Davidson/Giles Balleny 
  (Corporate Finance) 
                                     -------------------------- 
 

Notes for Editors

About ValiRx

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary

companies for further clinical development and commercialisation.   https://www.valirx.com/ 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

About Breast Cancer

Breast Cancer is any cancer that originates in breast tissue. Over 50,000 cases of Breast Cancer are identified in the UK every year, with over 99% of these in women.

Breast Cancer is identified by type, with the biochemical characteristics of the cancerous cells allowing doctors to assess the best course of treatment for the patient. Cells can display receptors that allow them to respond to hormones such as Estrogen, Progesterone and the HER2 protein. These receptors provide a target for treatments to work against the cancer. In triple negative breast cancer which accounts for around 15% of breast cancers, these receptors are not present on the cell, so treatment options are more limited, and prognosis poorer.

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRFLFIRADIELIL

(END) Dow Jones Newswires

September 16, 2021 01:59 ET (05:59 GMT)

1 Year Valirx Chart

1 Year Valirx Chart

1 Month Valirx Chart

1 Month Valirx Chart

Your Recent History

Delayed Upgrade Clock